2023 World Conference on Lung Cancer (Posters)-P2.11. A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer

P2.11. A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a presentation titled "A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer" at the WCLC 2023 conference. The study evaluated the efficacy and safety of tepotinib, a selective MET inhibitor, in patients with advanced solid cancers harboring MET exon 14 skipping mutation or MET amplification. The results of the study in non-small cell lung cancer (NSCLC) patients are reported. <br /><br />A total of 35 patients with advanced solid cancer were enrolled, and 24 of them were NSCLC patients. The majority of NSCLC patients had MET exon 14 skipping mutation. The objective response rate (ORR) in patients with MET exon 14 skipping mutation was 60%, and the disease control rate (DCR) was 100%. Median progression-free survival (PFS) in these patients was 9.0 months. For patients with MET amplification, the ORR was 66.7%, but the median PFS was 2 months.<br /><br />Exploratory analysis using liquid-based next-generation sequencing (NGS) testing showed that MET exon 14 skipping mutation was detected in 66.7% of baseline plasma samples. Patients with positive liquid biopsy results had an ORR of 72.7%, while those with negative liquid biopsy results had an ORR of 33.3%. The most frequently reported adverse events were peripheral edema, asthenia, and dyspepsia, mostly of grade 1 or 2.<br /><br />Overall, tepotinib showed favorable antitumor activity in NSCLC patients with MET exon 14 skipping mutation or amplification. The adverse events associated with tepotinib were generally low-grade and manageable. The study suggests that liquid-based NGS testing for MET exon 14 skipping mutation may have a potential role in predicting tepotinib response. The study was funded by Merck KGaA, Darmstadt, Germany.

Asset Subtitle

Yaewon Yang

Meta Tag

Speaker Yaewon Yang

Topic Metastatic NSCLC: Targeted Therapy - KRAS/MET

Keywords

tepotinib

MET exon 14 skipping mutation

MET amplification

non-small cell lung cancer

efficacy

safety

progression-free survival

liquid-based next-generation sequencing

liquid biopsy

adverse events